The NFAT family of transcription factors has been primarily related to T cell development, activation, and differentiation. Further studies have shown that these ubiquitous proteins are observed in many cell types inside and outside the immune system, and are involved in several biological processes, including tumor growth, angiogenesis, and invasiveness. However, the specific role of the NFAT1 family member in naive B cell proliferation remains elusive. Here, we demonstrate that NFAT1 transcription factor controls Cyclin E expression, cell proliferation, and tumor growth in vivo. Specifically, we show that inducible expression of NFAT1 inhibits cell cycle progression, reduces colony formation, and controls tumor growth in nude mice. We also demonstrate that NFAT1-deficient naive B lymphocytes show a hyperproliferative phenotype and high levels of Cyclin E1 and E2 upon BCR stimulation when compared to wild-type B lymphocytes. NFAT1 transcription factor directly regulates Cyclin E expression in B cells, inhibiting the G1/S cell cycle phase transition. Bioinformatics analysis indicates that low levels 2 of NFAT1 correlate with high expression of Cyclin E1 in different human cancers, including Diffuse Large B-cell Lymphomas (DLBCL). Together, our results demonstrate a repressor role for NFAT1 in cell cycle progression and Cyclin E expression in B lymphocytes, and suggest a potential function for NFAT1 protein in B cell malignancies.
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NFAT1 Transcription Factor Regulates Cell Cycle Progression and Cyclin E Expression in B Lymphocytes
Leonardo K. Teixeira The NFAT family of transcription factors encodes four different proteins (NFAT1-4) that are activated through the Calcium/Calcineurin signaling pathway. 1, 2 In resting cells, NFAT proteins are located in the cytoplasm in a hyperphosphorylated, inactive form. Calcium influx induced by different stimuli activates the serine/threonine phosphatase Calcineurin, which is able to dephosphorylate NFAT proteins, causing their nuclear translocation and DNA binding activity. 3, 4 Besides the canonical cytokines and cell surface markers regulated by NFAT transcription factors, several reports have shown that NFAT proteins control the activity of promoter and enhancer regions of many other inducible genes, such as FasL, Cox-2, and Vegf. [5] [6] [7] NFAT transcription factors have also been shown to regulate the expression of cell cycle-related genes, such as Cdk-4, Cyclin A2, C-Myc and p15 INK4b , [8] [9] [10] [11] indicating a central role for this family of transcription factors in cellular proliferation and tumorigenesis. Indeed, different NFAT family members have been related to tumor-associated processes, such as growth factor independency, apoptosis, angiogenesis, and invasiveness. 12, 13 Tumor development is driven by a succession of genetic changes that occur through aberrant cell division cycles, gradually converting normal cells into cancer cells. 14 Cell cycle progression is precisely controlled by the activation of specific cyclin-dependent kinases (CDKs) and their partner cyclins. [15] [16] Cyclin E normally accumulates at the G1/S phase transition, where it promotes S phase entry and progression by binding to and activating CDK2. In normal cells, Cyclin E/CDK2 activity is associated with DNA replication-related functions. [15] [16] [17] Ectopic expression of Cyclin E accelerates G1 progression, while inhibition of Cyclin E/CDK2 activity prevents S phase entry, indicating a positive role for this complex in G1/S transition. [18] [19] Overexpression of Cyclin E interferes with pre-replication complex assembly, causing replication stress and genomic instability. [20] [21] [22] [23] In malignant cells, deregulation of Cyclin E is associated with tumor development, aggressiveness, and poor outcome in different human cancers. [24] [25] [26] [27] [28] Transgenic mice models expressing high levels of Cyclin E in T lymphocytes are predisposed to lymphoid hyperplasia and malignant transformation, indicating a causative role for Cyclin E oncoprotein in lymphomas. 29, 30 Finally, Cyclin E overexpression has been correlated to poor prognosis in several human lymphomas, 25 as well as advanced stage and relapse in human B-cell leukemia patients. 31 Downloaded by [University of Sussex Library] at 14:11 11 July 2016 4
The NFAT family of transcription factors has been primarily described in T cells and further observed in many other cell types of the immune system. It has been shown that several NFAT family members, such as NFAT1 and NFAT2, are expressed in B lymphocytes and are required for B cell development and function upon activation. [32] [33] [34] Together with NFAT4, NFAT1 has been described to be involved in the expansion of mature follicular B cells, 35 and in B cell tolerance. 36 However, the role of NFAT1 transcription factor in cell cycle control of B lymphocytes remains to be elucidated. Here, we show that NFAT1 protein controls cell proliferation and Cyclin E expression in B lymphocytes. We demonstrate that NFAT1-deficient naive B lymphocytes show increased cell cycle progression and high levels of Cyclin E1 and Cyclin E2 upon stimulation when compared to control cells. We show that NFAT1 transcription factor directly binds the human Cyclin E1 and E2 promoters, and NFAT1 activation represses Cyclin E levels and the G1/S phase transition in B cells. Finally, we observe that low levels of NFAT1 correlate with high expression of Cyclin E1 in different human cancers, including Diffuse Large B-cell Lymphomas (DLBCL). Taken together, our results indicate a repressor role for NFAT1 in cell cycle progression and Cyclin E expression in B lymphocytes, and suggest a protective role for NFAT1 protein in B cell lymphoma.
Results
To address the role of NFAT1 transcription factor in cell cycle progression and tumorigenesis, we generated an NFAT1-inducible system in Chinese Hamster Ovary (CHO) cells stably-transfected with human NFAT1 cDNA. In this system, the NFAT1 protein is conditionally produced in the presence of tetracycline/doxycycline, which is able to inhibit the tetracycline repressor. 9 As observed, CHO cells do not show detectable levels of NFAT1 protein, which is only induced upon doxycycline treatment ( Figure 1A ). NFAT1 induction was associated with decreased number of cells and accumulation in G0/G1 cell cycle phases after doxycycline treatment ( Figures 1B and 1C , respectively).
Accordingly, NFAT1 induction was followed by decreased number of cells in S and G2/M phases ( Figure 1C ). Of note, doxycycline administration and NFAT1 expression did not lead to increased cell death as assessed by propidium iodide staining of Sub-G0 cells ( Figure 1D ). These results indicate that NFAT1 transcription factor controls cell cycle progression in CHO cells, and suggest a repressor role for NFAT1 during G1/S phase transition.
We next addressed the role of NFAT1 transcription factor in colony formation in vitro and tumor growth in vivo. In a semi-solid colony forming unit assay, NFAT1 induction caused a reduction in colony number and size when compared to CHO cells not treated with doxycycline ( Figure 1E ). As observed before, the reduction in colony number and size upon doxycycline treatment was not followed by increased cell death (data not shown). We next investigated the role of NFAT1 transcription factor in tumor growth and progression in vivo. Immunodeficient nude mice were inoculated subcutaneously with CHO cells and treated or not with tetracycline for 30 days to induce NFAT1 expression ( Figure 1F and 1G). While non-treated mice showed an exponential increase in tumor volumes starting at day 10, NFAT1 induction by tetracycline administration was able to inhibit tumor growth in vivo as early as 15 days after cell inoculation ( Figure 1F ). Furthermore, tetracycline-treated mice showed a 5-fold reduction in tumor volumes when compared to non-treated animals at 30 days after inoculation ( Figure 1F and 1G). Taken together, these results indicate a suppressor role for NFAT1 during cell cycle progression and tumor development in vivo.
NFAT proteins have been related to cellular proliferation in different cell types and tissues. However, the specific role of the major NFAT family member, NFAT1, in naive lymphocyte proliferation remains to be elucidated. In mammals, Cyclin E is represented by two functionally redundant family members, named Cyclin E1 and E2
(CCNE1 and CCNE2, respectively), which are involved in cell cycle regulation, specifically in the G1/S phase transition.
We then decided to further investigate the levels of Cyclin E1 and Cyclin E2 in NFAT1-deficient B lymphocytes. Both CCNE1 and CCNE2 mRNA and protein levels were increased in NFAT1-deficient B cells when compared to wild-type cells after PMA/Ionomycin stimulation ( Figure 3B and 3C, respectively). In fact, we have previously observed an overexpression of Cyclin E in total lymph nodes from NFAT1-deficient mice after ovalbumin challenge in vitro when compared to wild-type mice. 38 However, Cyclin E overexpression was not detected in primary CD4 + or CD8 + T lymphocytes from NFAT1-deficient mice upon anti-CD3 stimulation in vitro when compared to wild-type mice (data not shown). These results suggest that increased proliferation and Cyclin E overexpression in the B cell compartment contribute to the lymphocyte hyperproliferation phenotype observed in NFAT1-deficient mice.
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We next addressed whether NFAT1 was able to bind the human Cyclin E1 and E2 promoters in B cells. Bioinformatics promoter -Primer sets 1 and 2; see Materials and Methods). We also detected NFAT1 binding on a distal cluster of 7 NFAT-binding sites at the human Cyclin E2 promoter, located at positions -695 and -658 bp (Figures 4A and 4C, hCCNE2 promoter -Primer set 2; see Materials and Methods). Due to the close vicinity on both promoters, we could not precisely map whether NFAT1 binds all or a subset of these sites. Unfortunately, we were not able to address the two most proximal NFAT-binding sites at both Cyclin E1 and Cyclin E2 promoters (sites -507, -48 bp and -426, -187 bp, respectively; Figure 4A ). These sites are located on high GC-rich promoter regions, which are impeditive to productive PCR-based amplifications. As a positive control, we were able to detect Histone H4 acetylation on both Cyclin E1 and E2 promoters, indicating a chromatin state that is accessible to the recruitment of transcription factors and gene regulation ( Figures 4B and 4C ).
To determine whether NFAT1 transcription factor directly regulates Cyclin 1 and E2 expression, we evaluated
human Cyclin E promoter activity using Luciferase reporter assays. Wild-type and NFAT-mutant CCNE1 and CCNE2
proximal promoter regions were co-transfected with an Empty or NFAT1-encoding vector into Jurkat cells stimulated with PMA/Ionomycin. Overexpression of NFAT1 upregulated the activity of both wild-type Cyclin E1 and Cyclin E2 promoters ( Figure 4D and 4E, respectively). Mutation of all six putative NFAT-binding sites on either promoter inhibited responsiveness to NFAT1 overexpression ( Figure 4D and 4E, black bars). CCNE1-mutant promoter, which lacks the six NFAT-binding sites predicted by our bioinformatics analysis, is still responsive to NFAT1 overexpression ( Figure 4D , right bars), suggesting the presence of other putative NFAT-binding sites on the human CCNE1 proximal promoter region. Our data however showed that NFAT1 overexpression does not inhibit the activity of human CCNE1 and CCNE2 proximal promoters using Luciferase transactivation assays in Jurkat cells as initially anticipated. It is widely known that NFAT transcription factors interact with different transcriptional partners (activators or repressors) to promote gene expression under different cellular contexts. 2, 13 Therefore, it will be important to dissect the impact of individual NFAT-binding sites on these promoters as well as the co-factors that associate with NFAT1 to regulate Cyclin E expression during B lymphocyte development and function. Together, our data indicate that activation of NFAT1 transcription factor directly regulates the expression of Cyclin E1 and E2 in lymphocytes.
To further address the role of NFAT1 activation in the B cell compartment and its involvement in B cell malignancy, we took advantage of the B lymphocyte Burkitt's lymphoma Raji cell line. Raji cells show normal levels of NFAT1 transcription factor, which is dephosphorylated by Ionomycin-induced Calcium influx ( Figure 5A ). Interestingly, Ionomycin treatment alone was sufficient to interfere with Raji cell proliferation as measured by transition is characterized by phosphorylation of Rb protein on specific residues, which are modified by several Cyclin/CDK complexes, including Cyclin E/CDK2. 41, 42 In fact, Ionomycin treatment, which reduced the levels of Cyclin E1, decreased Rb phosphorylation in Raji cells after 24 hours ( Figure 5F ). Consistently, Rb phosphorylation on Thr821
and Thr826, which have been demonstrated to be phosphorylated by Cyclin E/CDK2, 41, 42 was drastically impaired upon Ionomycin treatment ( Figure 5F ). Taken together, our results suggest a repressor role for NFAT1 transcription factor in Cyclin E expression and cell cycle progression of B lymphocytes, indicating a cell type-specific proliferative capacity for NFAT1 in different lymphocyte compartments.
We next evaluated the relevance of our in vitro findings to human cancers. Expression data of 5,643 patients from 15 different tumor types were interrogated for mRNA expression levels of NFAT1 and Cyclin E1 (NFATC2 and CCNE1 genes, respectively) in The Cancer Genome Atlas (TCGA) database ( Figure 6A ). According to NFAT1 expression, two groups of samples were created, each one represented by 1/10 of the entries with the lowest and highest levels of NFAT1 expression ("Low NFAT1" and "High NFAT1", respectively; Figures 6A). Analysis of Cyclin E1 expression levels between these two groups showed a slight but significant negative association with NFAT1 expression, suggesting a mutually exclusive expression pattern between these two genes (p = 0.01219, Student's ttest; Figure 6B ). A similar negative association pattern was observed between NFAT1 and Cyclin E2 expression levels, however it did not reach statistical significance (data not shown). We next evaluated the Cyclin E1/NFAT1 expression ratio among all tumor types to identify human cancers with pronounced differences between NFAT1 and Cyclin E1 expression. Interestingly, the higher CCNE1/NFAT1 expression ratios were observed in Uterine Corpus Endometrial 
Discussion
In B lymphocytes, NFAT activation occurs mostly through BCR or CD40 stimulation, which causes activation of the Calcium/Calcineurin signaling pathway, leading to NFAT dephosphorylation and nuclear translocation. 43 In indicating that NFAT1 may play a negative role in B cell activation. 36 Furthermore, NFAT1/NFAT4-double deficient B lymphocytes showed a hyperresponsiveness to BCR stimulation and increased numbers of mature follicular B cells. 35 In that work, however, the authors have suggested that those effects were dependent on cell-extrinsic factors, such as the increased levels of Th2-type cytokines and the subsequent increase in IgG1 and IgE serum levels. 35 Along the same lines, NFAT1 activation or overexpression has been demonstrated to induce cell cycle arrest or cell death in T lymphocytes, Burkitt's lymphoma, and NIH 3T3 fibroblasts. [44] [45] [46] However, the molecular mechanisms by which NFAT1 induces cell cycle arrest in these cell types remain unknown. Together, our results support the notion that NFAT1 transcription factor works as a cell cycle repressor during the G1/S phase transition in B lymphocytes, and may contribute to controlling the tumorigenesis process.
NFAT proteins regulate the expression of many cell cycle-related genes, such as CDK4, CCNA2, C-Myc, and p15
INK4b in different models. [8] [9] [10] [11] It has been shown that NFAT1 directly binds specific sites at the CDK4 and Cyclin A2
promoters and negatively regulates the expression of both genes, suggesting an inhibitory role for NFAT1 in cell cycle progression. 8, 9 However, the role of NFAT1 protein in cell cycle regulation of B lymphocytes has not been fully addressed. Here, we show that NFAT1 deficiency causes Cyclin E1 and E2 overexpression at the mRNA level in B cells, which is followed by increased protein levels ( Figure 3 ). Furthermore, NFAT1 activation downregulates Cyclin E1 levels in the Raji B cells, consistent with a G1-phase arrest ( Figure 5 ). In fact, human Cyclin E1 and E2 promoters showed each six putative NFAT-binding sites at the proximal promoter region, several of which are conserved in mice and rats (data not shown). NFAT1 transcription factor was able to bind both Cyclin E1 and E2 promoters upon PMA/Ionomycin stimulation in Raji cells (Figure 4 ), supporting a repressive role for NFAT1 in Cyclin E/CDK2 activity and G1/S transition in B lymphocytes ( Figure 5 ).
Besides the upregulation of Cyclin E in NFAT1-deficient B lymphocytes, we have also observed that lack of NFAT1 caused an overexpression of other cyclin genes, notably Cyclin A2 and Cyclin H ( Figure 3A) . In a previous work, we have demonstrated that NFAT1 binds the mouse Cyclin A2 promoter and represses Cyclin A2 expression levels in CD4 + T lymphocytes, 9 another well-established activator of CDK2 function. NFAT proteins have not been related to Cyclin H regulation so far. Together with CDK7 and MAT1, Cyclin H forms a trimeric CDK-activating kinase (CAK) complex that directly phosphorylates and activates several CDKs, including CDK2. 47, 48 Therefore, it is possible that NFAT1 transcription factor controls CDK2-associated kinase activity through repression of Cyclin E, Cyclin A, and Cyclin H gene expression, while NFAT1-deficient B lymphocytes trigger a positive feedback loop for CDK2 activity that might contribute to B-cell hyperproliferation and malignancy. Interestingly, copy number gains at the 12q12-14 region, which contains the CDK2 gene, have been widely associated with human Diffuse Large B-Cell Lymphoma (DLBCL).
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Deregulation of NFAT signaling pathway has been associated with different human malignancies, including lymphomas and leukemias. [52] [53] [54] Sustained activation of Calcineurin has been observed in both human B and T cell lymphomas, and showed intrinsic effects in the proliferation and survival of these cells, highlighting the importance of NFAT transcription factors in these malignancies. 53 Specifically, it has been shown that NFAT2 preferentially localizes in the nucleus of Diffuse Large B-Cell Lymphomas (DLBCL) and Burkitt's lymphoma, potentially indicating NFAT2 activation in these malignancies. 52 Also, it has been shown that constitutive activation of NFAT2 induces the expression of B-Lymphocyte Stimulator (BLyS, also known as BAFF), CD40L (also known as CD154), and C-Myc in aggressive B-cell non-Hodgkin lymphoma (NHL-B) cells, which contribute to cell growth and survival of B cell lymphomas. [55] [56] [57] Even though there is substantial data regarding the oncogenic role of NFAT2 in B cell malignancies, the function of NFAT1 in normal and neoplastic B cells has not been extensively investigated. NFAT1-deficient mice older than 16 months spontaneously develop B cell neoplasms with features of anaplastic and/or plasmablastic plasmacytomas. 58 However, the molecular mechanisms for preferential formation of B cell malignancies in ageassociated NFAT1-deficient mice were not elucidated. Regarding the role of NFAT1 in other systems, it has been shown that lack of NFAT1 induces neoplastic transformation of cartilage cells and increased susceptibility to chemically-induced sarcoma formation in mouse models. 46, 59 Also, constitutively active NFAT1 (CA-NFAT1) was able to antagonize H-RasV12 oncogene-induced transformation of NIH 3T3 fibroblasts. 46 Collectively, these data suggest a tumor suppressor role for NFAT1 in different cell types. On the other hand, oncogenic properties have also been associated to NFAT1. It has been shown that integrin-signaling pathway activates NFAT1, as well as NFAT5, promoting cell migration and invasion of human breast and colon carcinoma cell lines. 60 More recently, in a model of intraepithelial pancreatic cancer, NFAT1 has been involved in the silencing of the p15 INK4b tumor suppressor locus through sequential recruitment of the histone methyltransferase Suv39H1 and heterochromatin protein HP1γ, promoting cell cycle progression. 11 It can be concluded from these data that NFAT1 transcription factor may present both oncogenic and tumor suppressor activities, depending on the cell type and cellular context considered. It will be important to determine the role of different NFAT family members, as well as their transcriptional partners (activators or repressors), in different cellular contexts, such as normal and neoplastic B lymphocytes.
In conclusion, we propose that NFAT1 is a repressor of cell cycle progression and Cyclin E expression in B cells. Indeed, we have observed a correlation between low levels of NFAT1 and high levels of Cyclin E1 in DLBCL, among other human tumors ( Figure 6 ). These results suggest that the loss of NFAT1 may contribute to B cell lymphoma development, and reestablishment of NFAT1 function may be an important therapeutic approach in B cell malignancies. isolated to  90% purity. The CHO-NFAT1 cell line was constructed by using the Flp-In T-Rex System (Invitrogen) as previously described.
Materials and Methods
Animals, Cell Cultures, and Reagents
(Cat# 115-006-075). The TLR ligands Pam3Cys, LPS, and CpG were kindly provided by Drs. M. Bozza and A. Nobrega (UFRJ, Brazil). PMA, Ionomycin, and the antibiotics doxycycline and tetracycline were all obtained from Calbiochem. were scored with Trypan Blue solution using a Neubauer chamber. For colony unit forming assays, plates were coated with 0.6% agarose-supplemented RPMI. CHO cells (810 2 cells/well) were cultivated in 0.3% agarosesupplemented RPMI. On top of these two layers, fresh RPMI medium containing or not doxycycline (1 g/mL) was added every 3 days for 20 days. Colony units were analyzed with a AxioVert S100 phase-contrast microscope (Carl Zeiss).
Proliferation Assays
RNase Protection Assay (RPA)
For RNase Protection Assays, naive B lymphocytes (210 6 cells) from NFAT1+/+ and NFAT1-/-mice were stimulated with PMA (10 nM) and Ionomycin (1 M) for 24 hours. Total RNA was extracted with TRIzol Reagent according to manufacturer's instructions (Invitrogen). The mRNA levels of c-MYC and the different Cyclins were analyzed with the mMYC, mCYC-1, and mCYC-2 multi-probe template sets by RPA kit according to manufacturer's instructions (RiboQuant, BD PharMingen). Transcript levels were analyzed by autoradiography, and RNA loading was estimated by measuring the intensities of two housekeeping genes (L32 and GAPDH).
Real-time PCR
For CCNE1 and CCNE2 relative expression assays, naive B lymphocytes (210 6 cells) from NFAT1+/+ and NFAT1-/-mice were stimulated with PMA (10 nM) and Ionomycin (1 M) for 24 hours. Gene expression was assessed by total RNA extraction using RNeasy Mini Kit (Qiagen), followed by cDNA synthesis via RT-PCR using random primers and the SuperScript II Reverse Transcriptase (Thermo Fisher Scientific). Relative quantification of CCNE1 and CCNE2 transcripts was performed by real-time PCR using a 7500 Real Time PCR System (Applied Biosystems) and the following TaqMan Gene Expression Assay kits: CCNE1, Mm00432367_m1; CCNE2, Mm00438077_m1; and HPRT, Mm00446968_m1 (Thermo Fisher Scientific). All procedures were performed according to manufacturer's instructions. Cyclin E expression levels were normalized to HPRT and are relative to the experiment with the lowest absolute Ct value obtained for NFAT1+/+ B lymphocytes.
Western Blot
To detect the presence of Cyclin E1, Cyclin E2 or NFAT1 proteins, naive B lymphocytes ( 
CCNE Promoter Analysis
Genomic sequences from Homo sapiens CCNE1 and CCNE2 promoters were obtained from the National
Center for Biotechnology Information (NCBI, Assembly GRCh38, Annotation Release ID: 107) on January 21, 2016.
Accession numbers were as follows: NC_000019.10 (CCNE1) and NC_000008.11 (CCNE2). Putative NFAT binding sites on the proximal 850 bp from both promoters were analyzed using TRANSFAC Professional and Match 1.0 programs (BIOBASE Biological Databases).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP experiments were performed as previously described before. Buffer for 10 minutes on ice as previously described. 9 Chromatin was sonicated 40 times of 30 seconds each, with 30-second intervals in between pulses to generate 200-500 bp DNA fragments (Bioruptor 300, Diagenode).
Immunoprecipitation was performed overnight at 4˚C with a set of NFAT1-specific antibodies (anti-67.1 and anti-T2B1), anti-acetyl-histone H4 antibody (Cat # 06-866, Upstate Biotechnology) or no antibody as a negative control. Immunocomplexes were captured with Protein A Sepharose CL-4B for 3 hours at 4C (GE Healthcare).
Formaldehyde crosslinks were reversed and DNA was purified by QIAquick Gel Extraction Kit according to manufacturer's instructions (Qiagen). Real-time PCR reactions were done with 1 L of the immunoprecipitated DNA using SYBR Green PCR Master Mix (Applied Biosystems). PCR conditions were as follows: 10 min at 95˚C, followed by 40 cycles of 15 sec at 95˚C and 1 min at 60˚C, completed by 1 min at 95˚C. Melting curve was performed from 50˚C to 90˚C, followed by 1 min at 60˚C (7500 Real Time PCR System, Applied Biosystems). Primers were used as follows:
hCCNE1 Primer set 1: 5' GCC TCA ACT GGA AGG CTT TA 3' and 5' GTG CAT TGG GTC GTT CAT TC 3' (167-bp product; Plasmid Construction pcDNA5/FRT/TO (pcDNA5-Empty vector) and pcDNA5-NFAT1 expression plasmids were previously described. 9 Human CCNE1 (-1 to -862) and CCNE2 (-1 to -838) proximal promoter regions (wild-type and NFAT-mutant constructs) were synthesized by GenScript, and later cloned into the pGL4.10 reporter plasmid (Promega) between
XhoI and BglII restriction sites. In the CCNE1 and CCNE2 NFAT-mutant promoter constructs, all six putative NFAT binding sites identified on each promoter were substituted with 5' ACTCT 3' sequence.
Luciferase Reporter Assay
Jurkat cells (310 6 cells) were electroporated in a 0. 
In Vivo Model of Tumorigenesis
Bioinformatics Analysis
Gene expression data derived from The Cancer Genome Atlas (TCGA) were downloaded on May 2015 from the cBioPortal for Cancer Genomics 63 for the following tumors: BLCA, BRCA, COADREAD, DLBC, GBM, HNSC, KIRC, LAML, LGG, LUAD, OV, PRAD, SARC, SKCM, and UCEC. Tumor samples were selected based on the expression of CCNE1 and NFATC2 (NFAT1), which should show a RSEM expression higher than zero and different from "Not Available" (NA). As a result, 5,643 samples were selected, and their respective CCNE1 and NFAT1 expression data were loaded and plotted using in-house R scripts based on default and ggplot2 plotting libraries. 64, 65 Statistical t-test analysis between the distribution of CCNE1 expression of the "Low NFAT1" and "High NFAT1" groups was performed in R using a Welch Two Sample t-test. 66 
Statistical Analysis
Statistical analyses between NFAT1+/+ and NFAT1-/-mice, and between control and treated groups, were determined using unpaired Student´s t test for single comparison. p < 0.05 was considered to be statistically significant. 
